Articles On Mach7 Technologies (ASX:M7T)

Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25...

Do you have a high tolerance for risk? If you do, you might want to check out the small cap ASX shares named below that brokers are tipping as buys with potential for massive returns. Let's see what they are saying about these stocks: Camp...

ASX medical imaging companies are capitalising on lucrative market of caring for US veterans with their innovative technologies Mach7  selected as solution provider for Veterans Health Administration National Teleradiology Program  SHG sec...

World Health Organsiation projects a shortfall of 10 million health workers by 2030 HeraMED’s platform helps healthcare providers manage maternity patients remotely Optiscan platform could address shortage of pathologists in Australia and...

 The little-known PharmX facilitates $20 billion of transactions between chemists and their suppliers annually  Mesoblast is one of the most closely watched of  today’s crop of last-minute quarterly reporters  Pro Medicus ‘mini- me’ Mach 7...

Investors with a higher tolerance for risk might want to check out the small cap ASX shares listed below that brokers are tipping as buys. Let's see what they are saying about these stocks: Aeris Resources Ltd (ASX: AIS) Bell Potter thinks...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

The share price of ASX penny stock Mach7 Technologies Ltd (ASX: M7T) has plunged more than 30% in the past year. Shares of the ASX health tech company closed on Friday at a new 52-week low of just 53 cents apiece. Long-term investors wil...

ASX health stocks flat for week in line while broader markets rise of 0.5% Nanosonics has risen ~17% in the past five days on its FY24 result Mach7 falls falls as investing in growth plans push out profit expectations    Healthcare and li...

The share price of Mach7 Technologies Ltd (ASX: M7T), a medical imaging systems provider, is down 4.2% today after the ASX healthcare company reported its FY24 results. Mach7 Technologies shares have not performed well over the past year...

ASX to open lower despite the Dow Jones hitting a new high Nvidia’s earnings report will be the major event later tonight Apple’s stock rose with the appointment of a new CFO   The ASX is expected to open lower on Wednesday despite the Do...

ASX health stocks rise at time of publishing, in line with broader markets amid mixed reporting season EBOS FY24 result in line with consensus as it looks to fill hole by loss of Chemist Warehouse contract Healius says pathology needs more...

ASX health stocks rise 0.9% in past five days as broader markets lift 1.2%, despite Friday selloff ImpediMed’s latest quarterly result shows sales momentum building for Sozo device  Cold-cathode X-ray machine developer MicroX makes progres...

Biotron jumps after Phase 2 trial success Biotron (ASX:BIT) jumped +15% this morning after announcing promising results from its BIT225-011 Phase 2 clinical trial, indicating that the primary objectives of the study have been achieved. This...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Merewether C...

ASX health stock rise  in past five days along with broader markets  Wound care company Polynovo achieves its first ever $10m+ revenue month in April Power says Neuren selloff a “complete overreaction” after US partner Arcadia’s latest res...

Several ASX medtech companies have upcoming catalysts in 2024 as they look to transform healthcare  Imricor preparing to treat its first ventricular tachycardia patient this quarter  Optiscan on schedule for launch of breast surgical devic...

If you have a higher than average tolerance for risk, then you might want to consider adding some small cap exposure to your portfolio. But which small cap ASX shares should you buy? Listed below are three that Morgans rates very highly. He...

Small-cap shares suffered greatly during the period of 13 interest rate rises over 2022 and 2023. But with inflation cooling and the prospect of rate cuts coming, the little guys are starting to play catch up to the medium and large caps....

ASX health sector rises in line with broader markets in the past five days  AdAlta reports positive Phase 1 extension trial results of AD-214 into IPF Mach7 signs $3.1 million, three-year renewal contract with Penn State Health Morgans h...

    Wall Street falls, Nvidia soars BTC nears all-time highs Gold to move even further?   The ASX is poised to start flat on Tuesday, after overnight losses on Wall Street. At 8am AEDT, the ASX 200 index futures contract was pointing up...

Futures predict the ASX200 will trade mostly flat this morning, maybe down just a touch on open. US markets were down a little ahead of the next round of economic data. The Nasdaq dropped 0.4 per cent, the Dow Jones shed a quarter of...

ASX health sector lifts in line with broader markets as reporting season comes to end Morgans upgrades Polynovo as total revenue rises 65.6% on pcp to $48.8 million  Nanosonics cites hospital budgetary pressures as deferring purchasing dec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AGI)) - Ainsworth Game Technology ((ART)) - Airtasker ((ALX)) - Atlas Arteria ((AFG)) - Australian Finance Group ((CAJ)) - Capitol Health ((CLU)) - Cluey ((DOC)) - Docto...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.40% to 6,948.80. A poor session to kick off the new trading week with the ASX snubbing the strength in...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

Mach7 Technologies reports third consecutive year of record sales growth in FY23 View on enterprise imaging extends beyond radiology CEO Mike Lampron says AI hurdles right now need to be overcome Morgans healthcare analyst Scott Power lik...

Mach 7 Tech is rated Overweight by Wilsons, with price target of almost double Goldman slapped a Buy rating on neobank Judo Capital   Wilsons says Mach7 could be worth almost double current price Wilsons has initiated coverage of Mach7 Te...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

ASX health sector rises in line with broader markets as reporting season comes to end EBR Systems on schedule for key US FDA submission in Q1 CY24 for (WiSE) CRT system Health imaging company Mach7 achieves record sales order book of $40.3...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown   Despite the recent rally, the ASX Healthcare Index (XHJ) is...

ASX health sector falls in mixed week of FY23 results as reporting season continues Monash IVF reports solid FY23 result and forecasts higher IVF cycles going forward Ramsay healthcare plunges on disappointing FY23 result and cut in final...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The Mach7 Technologies Ltd (ASX: M7T) share price is having a strong finish to the week. In morning trade, the ASX health technology share is up 7% to a 52-week high of 97.5 cents. Why is this ASX share shooting higher? Investors have been...

The ASX will open lower on Friday as earnings weighed on Wall Street The “fear gauge” CBOE index is at lowest since 2020 Bitcoin spot ETFs to significantly increase BTC demand, says analyst   Local shares are set to open lower on Friday a...

ASX health stocks have fallen in the past five days in line with broader markets Mach7 wins a US$60 million Veterans contract – the most significant in its history Neuren completes recruitment for Phase II trial of NNZ-2591 in Phelan-McDer...

Lumos soars after US FDA approval for FebriDx rapid, point-of-care test Emyria will buy the Pax Centre for $1.7 million following psychedelic medicine law changes in Australia Rhythm Biosciences establishes UK subsidiary as part of strateg...

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

ASX health stocks rise in the past five days in line with broader markets Immutep  surges 46% after positive Phase 2 results into lung cancer Avita Medical falls 28% in past five days despite reporting “solid Q1 FY23” results Healthcare a...

ASX health stocks fall 0.8% in the past five days in line with broader markets following latest rate hike Investors rewarding health stocks with near term catalysts in 2023, including Neuren and Impedimed Health imaging stock Volpara recor...

Mach7 primed for growth as move towards enterprise rather than departmental imaging grows Company’s three modular products are a unique fit for use case of enterprise imaging Mach7 landing big clients as it works to solve tomorrow’s probl...

The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect...

Mach7 (M7T) receives a $7.1 million order from Adventist Health for Mach7 picture archiving and communication systems (PACS) for another 15 hospitals This marks the final deployment phase of a 22-hospital contract signed in January 2021,...

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABC)) - Adbri ((AHL)) - Adrad ((AIS)) - Aeris Resources ((AMX)) - Aerometrex ((AOF)) - Australian Unity Office Fund ((AVG)) - Australian Vintage ((BBT)) - BlueBet Holdin...

The ASX is set to track Wall Street and move higher at the open The DoE says Covid-19 came from a ‘lab leak’ Coinbase to suspend trading of Binance USD   The ASX is set to open stronger on Tuesday after US stocks rose in New York. At 8am...

ASX health stocks fall 1.2% in the past five days  as macro economic factors weigh on broader markets Monash IVF has reported a solid H1 FY23 result with underlying NPAT of $12.6m, ahead of guidance Pharmaceutical distribution group  EBOS...

If you have a high tolerance for risk, then you might want to consider adding some small cap exposure to your portfolio. But which small cap ASX shares should you buy? Listed below are two that Morgans rates very highly. Here’s why it is...